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Abstract
Background: The incidence of tuberculous pericarditis has increased in Africa as a result of the
human immunodeficiency virus (HIV) epidemic. However, the effect of HIV co-infection on clinical
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features and prognosis in tuberculous pericarditis is not well characterised. We have used baseline
data of the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry to assess
the impact of HIV co-infection on clinical presentation, diagnostic evaluation, and treatment of
patients with suspected tuberculous pericarditis in sub-Saharan Africa.
Methods: Consecutive adult patients in 15 hospitals in three countries in sub-Saharan Africa were
recruited on commencement of treatment for tuberculous pericarditis, following informed
consent. We recorded demographic, clinical, diagnostic and therapeutic information at baseline,
and have used the chi-square test and analysis of variance to assess probabilities of significant
differences (in these variables) between groups defined by HIV status.
Results: A total of 185 patients were enrolled from 01 March 2004 to 31 October 2004, 147
(79.5%) of whom had effusive, 28 (15.1%) effusive-constrictive, and 10 (5.4%) constrictive or acute
dry pericarditis. Seventy-four (40%) had clinical features of HIV infection. Patients with clinical HIV
disease were more likely to present with dyspnoea (odds ratio [OR] 3.2, 95% confidence interval
[CI] 1.4 to 7.4, P = 0.005) and electrocardiographic features of myopericarditis (OR 2.8, 95% CI
1.1 to 6.9, P = 0.03). In addition to electrocardiographic features of myopericarditis, a positive HIV
serological status was associated with greater cardiomegaly (OR 3.89, 95% CI 1.34 to 11.32, P =
0.01) and haemodynamic instability (OR 9.68, 95% CI 2.09 to 44.80, P = 0.0008). However, stage
of pericardial disease at diagnosis and use of diagnostic tests were not related to clinical HIV status.
Similar results were obtained for serological HIV status. Most patients were treated on clinical
grounds, with microbiological evidence of tuberculosis obtained in only 13 (7.0%) patients.
Adjunctive corticosteroids were used in 109 (58.9%) patients, with patients having clinical HIV
disease less likely to be put on them (OR 0.37, 95% CI 0.20 to 0.68). Seven patients were on
antiretroviral drugs.
Conclusion: Patients with suspected tuberculous pericarditis and HIV infection in Africa have
greater evidence of myopericarditis, dyspnoea, and haemodynamic instability. These findings, if
confirmed in other studies, may suggest more intensive management of the cardiac disease is
warranted in patients with HIV-associated pericardial disease.
Background
Pericarditis is a common disorder that has multiple causes
and presents in various clinical settings [1]. Tuberculosis
is responsible for more than 50% of cases of pericarditis
in developing countries where tuberculosis remains a
major public health problem [2]. By contrast, Mycobacte-
rium tuberculosis infection accounts for less than 5% of
cases of pericarditis in industrialised countries [1]. In
Africa, the incidence of tuberculous pericarditis is said to
be rising as a direct result of the human immunodefi-
ciency virus (HIV) epidemic [3-7]. There is a strong asso-
ciation between HIV infection and tuberculous
pericarditis in endemic regions, where 40–75% of
patients with large pericardial effusion (suspected to be
tuberculosis) are infected with HIV [2,3].
The effect of HIV infection on the clinical presentation,
response to treatment and outcome of patients with tuber-
culous pericarditis is not well characterised [8]. HIV
infected patients with tuberculous pericarditis have been
found to be more likely than HIV negative patients to
have disseminated tuberculosis, raising the possibility
that dissemination may worsen long-term outcome [5].
Preliminary evidence suggests that HIV infection may be
associated with higher mortality in tuberculous pericardi-
tis; mortality with anti-tuberculosis chemotherapy ranged
from 8% to 17% in the pre-HIV era [9-12], whereas higher
mortality rates of 17–34% have been reported in HIV
infected individuals [13].
We have conducted the first African multi-centre prospec-
tive observational registry of the clinical presentation,
diagnostic evaluation, initial treatment, and outcome of
patients with suspected tuberculous pericarditis in the
HIV era. This study, which is called the Investigation of
the  Management of Pericarditis  in  Africa  (IMPI Africa)
Registry, was established mainly to obtain contemporary
information that is required for the design of a clinical
trial of the effectiveness of adjunctive steroids in tubercu-
lous pericarditis in the HIV era [2]. In this report we have
used the baseline data of the IMPI Africa Registry to assess
the impact of clinical HIV disease on the clinical charac-
teristics, diagnostic work-up, and initial treatment of
patients with suspected tuberculous pericarditis.
Methods
The IMPI Africa registry is a simple pragmatic multi-centre
prospective observational study of patients admitted toBMC Infectious Diseases 2006, 6:2 http://www.biomedcentral.com/1471-2334/6/2
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hospital with suspected tuberculous pericarditis which
was designed to assess the impact of HIV infection on clin-
ical presentation, diagnostic evaluation, initial treatment,
and outcome of patients with tuberculous pericarditis in
Africa. We set out to enrol a minimum of 100 consecutive
suspected tuberculous pericarditis patients presenting to
collaborating physicians over 6 months, and follow them
prospectively for 6–12 months. The study was approved
by the research ethics committee of the University of Cape
Town, South Africa, and all participants gave written
informed consent.
Twenty seven hospital-based physicians from eight Afri-
can countries (Cameroon, 2; Ghana, 1; Kenya, 1; Lesotho,
1; Nigeria, 1; South Africa, 19; Uganda, 1; Zimbabwe, 1)
were invited by electronic mail in January 2004 to partic-
ipate in the study. These physicians had expressed an
interest in the project to one of the investigators (BMM).
Fifteen physicians from three countries (Cameroon, 1;
Nigeria, 1; and South Africa, 13) contributed patients to
the IMPI Africa Registry (56% response rate). Twelve of
the 15 physicians were affiliated to medical schools, and
three (all in South Africa) were based in district general
hospitals.
Suspected tuberculous pericarditis was defined as a
patient presenting to hospital with a clinical syndrome of
pericardial disease which was suspected to be caused by
tuberculosis on the basis of clinical and/or laboratory
findings leading to the commencement of anti-tuberculo-
sis chemotherapy according to the national tuberculosis
control programme [14] Consecutive incident cases of
suspected tuberculous pericarditis were enrolled. Adult
patients were eligible for inclusion in the study if the col-
laborating physician felt sufficiently confident with the
diagnosis of tuberculous pericarditis to commence anti-
tuberculosis treatment. The management of each patient
was at the discretion of the collaborating physician in
keeping with the observational nature of the study.
Pericardial disease was classified as acute non-effusive
pericarditis, pericardial effusion, effusive-constrictive
pericarditis, or constrictive pericarditis on the basis of the
collaborating physician's assessment of clinical and imag-
ing information.
We classified tuberculous pericarditis as 'definite' or
'probable' depending on the amount of clinical and bac-
teriological information supporting the diagnosis of
tuberculosis, or 'not tuberculous pericarditis' when an
alternative (non-tuberculous) cause of pericarditis was
found. A diagnosis of 'definite' tuberculous pericarditis
was based on the demonstration of tubercle bacilli in peri-
cardial fluid (smear and/or culture) or on histologic sec-
tion of the pericardium; 'probable' tuberculous
pericarditis on the proof of tuberculosis elsewhere in a
patient with otherwise unexplained pericarditis, on the
basis of indirect tests (e.g., adenosine deaminase level ≥
40 IU/l in pericardial fluid) and/or an appropriate
response to a trial of anti-tuberculosis chemotherapy.
The HIV status of the patients was based on the results of
serological testing for HIV. However, serological testing
for HIV is not always available or offered in some medical
institutions in Africa. Therefore, the physicians were
requested to state whether they suspected HIV infection
on clinical grounds and to classify each patient as either
having evidence of 'clinical HIV disease' or 'no clinical
HIV disease' without regard to the HIV serological status
of the patient. This assessment was left to the discretion of
the collaborating physician, and no criteria were specified.
The effect of pericardial disease on the functional capacity
of each patient was defined using New York Heart Associ-
ation (NYHA) criteria as class I (no limitation in physical
activity), class II (ordinary physical activity results in dys-
pnoea), class III (minimal physical activity results in dys-
pnoea), or class IV (dyspnoea at rest) [15].
Haemodynamic instability was defined by the presence of
at least two of these signs: pulse rate > 100 beats/minute,
systolic blood pressure < 100 mmHg, and cardiac tam-
ponade requiring pericardiocentesis. The radiological,
electrocardiographic, echocardiographic, and laboratory
results were based on the report provided by the collabo-
rating physician without central verification.
Demographic, clinical, diagnostic and therapeutic infor-
mation was captured by means of a standardized data col-
lection form (available on request) and transmitted (by
fax or e-mail) to the IMPI Africa Coordinating Centre at
the Cardiac Clinic, Groote Schuur Hospital, Cape Town,
South Africa. Enrolment into the registry started on 1
March 2004 in 11 hospitals and up to two months later in
the other four, and ended on 31 October 2004. Patients
were reviewed for the study outcomes at three, six and 12
months following entry into the registry, with a minimum
follow-up period of 6 months for all participants. Patient
follow-up was carried out by personal interview, failing
which telephonic enquiry and postal services were used.
On enrolment, each patient provided a contact person
(next of kin or neighbour) who could be contacted if the
patient's whereabouts were not known at the time of fol-
low-up. In the event of death or illness the contact person
would be able to provide information. In the event of
death, every effort was made to obtain a copy of the death
certificate. We also used the services of the South African
Department of Home Affairs (for South African centres)
and a private detective company to obtain the vital status
of patients lost to follow-up. The follow-up phase of theBMC Infectious Diseases 2006, 6:2 http://www.biomedcentral.com/1471-2334/6/2
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study ended on 30 April 2005, and (follow-up) data will
be reported separately.
Data were analysed using Epi Info 3.3 (CDC, Atlanta, GA,
USA). We used the chi-square test (or Fisher's exact test for
variables with small number of expected frequencies) and
analysis of variance to asses differences between categori-
cal and continuous variables respectively. Significance
tests were two-tailed and statistical significance was
defined at the 5% alpha level. All patients were stratified
by clinical HIV disease status and entered in the analyses
regardless of the final diagnosis.
Results
Clinical profile
One hundred and eighty-five patients were recruited, with
the number recruited per geographic region varying from
17 (9.2%) in Yaoundé, Cameroon to 58 (31.4%) in the
Eastern Cape Province of South Africa (Table 1). The gen-
eral characteristics of the study population are shown in
Table 2, stratified by clinical HIV disease status. The
median age of the patients at diagnosis was 33 (range 14–
87) years, and 82 (56%) were men. The proportions of
patients in NYHA functional classes I to IV were 21.1%
(39/185), 37.3% (69/185), 25.4% (47/185), and 16.2%
(30/185), respectively. Pericardial effusion was diagnosed
in 79.5%, effusive-constrictive pericarditis in 15.1%, acute
dry pericarditis in 3.8%, and constrictive pericarditis in
1.6%. Haemodynamic instability was reported in 49
(26.5%) patients, 38 (77.6%) of whom required pericar-
diocentesis to relieve cardiac tamponade.
Seventy-four (40.0%) patients had clinical evidence of
HIV disease. There was significant geographical variation
in the proportion of patients with clinical HIV disease (P
= 0.0001), with Cameroon having the highest (88.2%)
and Nigeria the lowest (19.4%). In South Africa, patients
recruited from the Gauteng Province had the highest prev-
alence of clinical HIV disease (52.4%), and the Western
Cape Province the lowest (31.4%). Patients with clinical
HIV disease were more likely to present in worse dysp-
noea (P = 0.004). There was no significant association
between age, gender, haemodynamic stability and clinical
HIV disease (Table 2).
We evaluated the ability of the physicians to predict sero-
logical HIV status by using clinical criteria of HIV disease
in a subset of 96 patients who were tested for HIV. There
was strong agreement between clinical signs of HIV dis-
ease and serological HIV status (Table 3). The sensitivity
of clinical signs of HIV disease was 75.5%, specificity
88.4%, positive predictive value 88.9%, and negative pre-
dictive value 74.5%, which compare favourably with pre-
vious studies in Africa [16]. There was, however, a bias in
HIV testing, with tests done in 53/74 (72%) of cases with
clinical HIV disease and 43/111 (39%) of cases without
clinical HIV disease (p < 0.001). This bias may have
affected the findings for sensitivity and specificity of clin-
ical diagnosis and may have influenced the reliability of
observations regarding associations with HIV serostatus.
Diagnostic evaluation
The chest radiograph and echocardiogram were per-
formed in 179 (96.8%) and 174 (94.1%) patients, respec-
tively. Electrocardiography (ECG) was carried out in 119
(64.3%) patients, and only 69 (37.3%) were subjected to
pericardiocentesis. There was no significant variation in
the diagnostic tests used by clinical HIV disease status
(Table 4, 5, 6). Forty-eight (26.8%) patients had radiolog-
ical signs of active pulmonary tuberculosis (Table 4).
Patients with clinical HIV disease were more likely to have
radiological signs of active pulmonary tuberculosis (P =
Table 1: Geographic distribution of the hospitals and study population
Country Region Hospital Number of patients recruited (%)
Cameroon Centre Centre Hospitalier et Universitaire, Yaoundé 17 (9.2)
Nigeria South West University College Hospital, Ibadan 31 (16.8)
South Africa Eastern Cape Nelson Mandela Academic, Umtata 42 (22.7)
Livingstone and Provincial, Port Elizabeth 10 (5.4)
Cecilia Makiwane, East London 6 (3.2)
Western Cape Groote Schuur and GF Jooste, Cape Town 17 (9.2)
Karl Bremer, Bellville 13 (7.0)
George, George 3 (1.6)
Eersterivier, Cape Town 2 (1.1)
Guateng Dr George Mukhari, Tshwane 15 (8.1)
Chris Hani Baragwanath, Johannesburg 6 (3.2)
KwaZulu Natal Prince Mshiyeni, Durban 16 (8.6)
King Edward VIII, Durban 7 (3.8)
Total 185 (100.0)BMC Infectious Diseases 2006, 6:2 http://www.biomedcentral.com/1471-2334/6/2
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0.003). The most prevalent ECG changes were micro volt-
age (22.7%), S-T segment elevation (20.2%), and P-R seg-
ment deviation (16.8%). Atrial fibrillation and electrical
alternans were present in 12 (10.1%) and 11 (9.2%)
patients with ECGs, respectively (Table 5). There was no
statistically significant relationship between clinical HIV
disease and atrial fibrillation (P = 0.09), electrical altern-
ans (P = 0.43), micro voltage (P = 0.27), and PR segment
deviation (P = 0.09). However, clinically HIV infected
patients were more likely to have ST segment elevation (P
= 0.03), which is indicative of myocardial injury.
Sixty nine patients had pericardiocentesis for diagnostic
(N = 31) or therapeutic (N = 38) reasons (Table 6). Results
of chemistry (adenosine deaminase [ADA]) and micro-
scopic analyses (Ziehl-Neelsen stain for acid fast bacilli),
and Mycobacterium tuberculosis culture were available
for 35, 55, and 16 patients, respectively. Thirteen (7.0%)
patients had definite tuberculous pericarditis, 166
(89.7%) probable tuberculous pericarditis, and six (3.2%)
patients had an alternative diagnosis. There were no sig-
nificant differences between clinically HIV infected
patients and those who were not with regard to having a
high ADA level (> 40 IU/L) or presence of acid fast bacilli
on microscopic analysis (P = 0.79 and P = 0.61, respec-
tively).
Table 2: Clinical characteristics of the study population by clinical HIV status
Clinical HIV disease No clinical HIV disease P
Number of patients 74 (40) 111 (60)
Age (median, range), years 36 (18–87) 32 (15–79) 0.14
Gender
 Men
42 (40.8) 61 (59.2)
 Women
32 (39.0) 50 (61.0) 0.81
Region
 Eastern Cape, SA+
20 (34.5) 38 (65.5)
 Western Cape, SA
11 (31.4) 24 (68.6)
 Ibadan, Nigeria
6 (19.4) 25 (80.6) 0.0001
 KwaZulu Natal, SA
11 (47.8) 12 (52.2)
 Gauteng, SA
11 (52.4) 10 (47.6)
 Yaoundé, Cameroon
15 (88.2) 2 (11.8)
Pericardial syndrome
 Acute
1 (14.3) 6 (85.7)
 Effusion
65 (44.2) 82 (55.8)
 Effusive-constrictive
8 (28.6) 20 (71.4)
 Constrictive
0 (0.0) 3 (100.0) 0.09
NYHA++ Functional Class
 I
8 (20.5) 31 (79.5)
 II
27 (39.1) 42 (60.9)
 III
20 (42.6) 26 (57.4)
 IV
19 (63.3) 11 (36.7) 0.004
Haemodynamic instability**
 Yes
24 (49.0) 25 (51.0)
 No
50 (36.8) 86 (63.2) 0.13
Tamponade requiring centesis 17 (44.7) 21 (55.2) 0.97
Values are median (range) and absolute counts (percentages)
+SA, South Africa; ++NYHA, New York Heart Association (I, No limitation of physical activity; II, Slight limitation of physical activity; III, Marked 
limitation of physical activity; and IV, Unable to carry out any physical activity without discomfort); **Pulse rate more than 100 bpm, Systolic blood 
pressure less than 100 mmHg and or tamponade requiring centesis.
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Initial treatment
One hundred and seventy-eight patients (96.2%) were on
four-drug anti-tuberculosis chemotherapy for new tuber-
culosis cases and the rest were on five drugs for re-treat-
ment of tuberculosis. A total of 109 (58.9%) patients were
put on adjunctive corticosteroids. Clinically HIV infected
patients were less likely to be put on an adjunctive corti-
costeroid (P = 0.001). Seven patients (10% of patients
with clinical HIV disease) received antiretroviral drugs, all
of whom were recruited in the non-South African centres.
All drugs (anti-tuberculosis, corticosteroids, and antiretro-
viral drugs) were given orally. In particular, none of the
patients who received steroids were administered these
agents by intra-pericardial or intravenous routes.
Findings in the sub-group with known HIV serological 
status
HIV serological tests were conducted in 96 participants
(55%); there were no significant age and sex differences
between participants with and without HIV serological
results. There were, however, major regional differences in
the proportions of participants who were tested for HIV,
with Nigeria and Cameroon having the highest testing
rates of 94% of participants tested in each centre, 66% in
the Western Cape, 29% respectively in Gauteng and the
Eastern Cape, and 22% in Kwa Zulu Natal. Results of the
analyses by HIV serological status are shown in additional
file 1 (Tables S1-S4). Like patients with clinical evidence
of HIV infection, those who had a serological diagnosis of
HIV were more likely to have dyspnoea (P = 0.02) and ST
segment elevation on the electrocardiogram (P = 0.01). In
addition, patients with serological evidence of HIV infec-
tion were more likely to have haemodynamic instability
(P = 0.0008) and radiological signs of cardiomegaly (P =
0.01) than HIV uninfected patients, but there was no rela-
tionship between active pulmonary tuberculosis and sero-
logical HIV status (P = 0.19).
Discussion
This prospective observational study indicates that 40% of
patients presenting to hospital with suspected tuberculous
pericarditis in parts of Cameroon, Nigeria and South
Africa have clinical features of HIV infection. This study
reveals for the first time that patients with clinical features
of HIV infection have a different clinical presentation of
the cardiac disease. Patients with clinical HIV disease and
tuberculous pericarditis have greater dyspnoea and elec-
trocardiographic ST segment changes that are suggestive
of myopericarditis. In addition, a positive HIV serostatus
was associated with greater cardiomegaly and haemody-
namic instability in these patients. These data suggest that
there may be greater pericardial fluid accumulation and
myocardial involvement in patients with HIV-associated
pericardial tuberculosis. These findings, if confirmed in
prospective studies with less biased assessment of HIV sta-
Table 3: Ability of collaborating physicians to predict HIV 
serological status from clinical assessment of HIV disease
HIV Serological Status
Clinical HIV Disease Positive Negative
Yes 40 5 45
No 13 38 51
53 43 96
Sensitivity: 40/53 = 75.5%
Specificity: 38/43 = 88.4%
Positive predictive value: 40/45 = 88.9%
Negative predictive value: 38/51 = 74.5%
Table 4: Chest X-ray changes in the study population by clinical HIV status
Feature Clinical HIV disease No clinical HIV disease P
Number of patients
Cardiomegaly
72 (40.2) 107 (59.8) 0.39
 Yes
62 (42.2) 85 (57.8) 0.25
 No
10 (31.3) 22 (68.8)
Pericardial calcification
 Yes
1 (20.0) 4 (80.0) 0.33
 No
71 (40.8) 103 (59.2)
Active PTB*
 Yes
28 (58.3) 20 (41.7) 0.003
 No
44 (33.6) 87 (66.4)
Values are absolute counts (percentages)
* PTB: Pulmonary tuberculosis
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tus, suggest that tuberculous pericarditis is a more severe
cardiac disease in people with HIV/AIDS.
Preliminary evidence from small single centre studies of
tuberculous pericarditis in African patients infected with
HIV has suggested that tuberculous pericarditis occurs in
the early stages of HIV disease. In a Tanzanian study of
HIV and tuberculous pericarditis, only 5 of the 28 HIV
infected patients had clinical signs of HIV infection, sug-
gesting that pericardial disease was an early manifestation
of HIV infection in Tanzania [3]. Our finding that nearly
half of the patients with suspected tuberculous pericardi-
tis have overt features of HIV infection may be in keeping
with the maturity of the HIV/AIDS epidemic in many
parts of Africa, which is associated with a greater propor-
tion of patients presenting in advanced stages of HIV dis-
ease than was the case 15 years ago when many of the
studies were conducted [3-7]. There was, however,
marked geographic variation in the prevalence of clinical
HIV disease in our study which correlated with the known
epidemiology of the HIV epidemic in Africa, with the
exception of the Cameroon. In Cameroon we found a
prevalence of clinical HIV disease in patients with sus-
pected tuberculous pericarditis of 88.2%, compared to a
much lower HIV seroprevalence of 5.5% in the general
population [18].
There is a strong association between HIV infection and
extra-pulmonary tuberculosis; about 67% of patients with
extra-pulmonary tuberculosis are HIV infected in Zaire
[17]. In Tanzania, 72% of patients with pericardial effu-
sion were HIV seropositive, suggesting that pericardial
effusion is strongly associated with HIV infection [3]. Of
the 96 patients who were tested for HIV in the IMPI Africa
registry, 53 (55.2%) were HIV infected.
A study of 88 patients from the Western Cape Province of
South Africa, which included 39 HIV infected patients,
suggested that there were no differences in the electrocar-
diographic findings between HIV infected and HIV nega-
tive patients with tuberculous pericarditis [19]. By
contrast, we observed that more patients with clinical HIV
disease than those without had ST segment elevation on
ECG (30.4% versus 13.7%), and there was a trend towards
greater PR segment deviation, changes which are associ-
ated with involvement of the superficial layers of the myo-
cardium in pericarditis [20]. The association of HIV
infection with ST elevation on ECG was confirmed when
the analyses were restricted to the sub-group of patients
with known HIV sero-status.
In the pre-HIV era, changes of acute pericarditis in tuber-
culous pericarditis were reported in a small minority of
patients (i.e., 9–11%) [19,21,22]. Whether the greater
prevalence of electrical evidence of acute pericarditis bears
relation to greater myocardial involvement in the form of
a myopericarditis in immunocompromised patients
remains to be established by prospective study [23-25]. It
Table 5: Electrocardiographic changes in study population by clinical HIV status
Feature Clinical HIV disease No clinical HIV disease P
Number of patients
PR segment deviation
46 (38.7) 73 (61.3) 0.62
 Yes
11 (55.0) 9 (45.0) 0.09
 No
35 (35.4) 64 (64.6)
ST segment elevation
 Yes
14 (58.3) 10 (41.7) 0.03
 No
32 (33.7) 63 (66.3)
Micro voltage
 Yes
8 (29.6) 19 (70.4) 0.27
 No
38 (41.3) 54 (58.7)
Electrical alternans
 Yes
5 (45.5) 6 (54.5) 0.43
 No
41 (38) 67 (62)
Atrial fibrillation
 Yes
2 (16.7) 10 (83.3) 0.09
 No
44 (41.1) 63 (58.9)
Values are absolute counts (percentages)
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is possible that left ventricular dysfunction, associated
with myopericarditis in patients with tuberculous pericar-
ditis and HIV, may account for the greater dyspnoea that
was observed in these patients.
What are the limitations of the registry?
Our study methods can be criticised on several grounds.
First, the economic circumstances of medical practice in
many African countries result in frequent shortages that,
in this study, preclude complete data acquisition in every
patient. For example, 6% of patients enrolled in the regis-
try did not have access to echocardiography for confirma-
tion of the diagnosis of pericardial disease. Secondly, the
lack of bacteriological confirmation of tuberculosis in the
vast majority and HIV serology tests in half of the patients
results from similar considerations. It should be noted,
however, that the most intense investigation may fail to
yield clear information as to aetiology in patients present-
ing with pericardial effusion [26]. The associations with
clinical HIV disease should be interpreted with caution,
and, given the low percentage tested, even associations
with HIV seropositivity may have been subject to bias.
This was a simple, large, prospective, observational study
in a resource poor environment in which the definition of
clinical and laboratory abnormalities were based on self-
reports of the collaborating physicians without the verifi-
cation of the primary data at a central site.
Conclusion
What are the implications for clinical practice?
Patients with suspected tuberculous pericarditis and HIV
infection have evidence of a myopericarditis, poorer func-
tional class, and haemodynamic instability in Africa.
These factors are likely to be associated with a poorer
prognosis, and may identify a high risk group that
requires more intensive management of the cardiac dis-
ease and consideration of earlier treatment of the HIV dis-
ease.
What are the implications for research?
There are at least three research questions that arise from
this work. First, the impact of HIV infection on outcome
in tuberculous pericarditis has not been addressed in
long-term studies. The results of the follow-up of patients
enrolled in this study should provide useful information
in this regard. Second, the impression that tuberculous
pericarditis is a myopericarditis in people with advanced
HIV disease requires confirmation in prospective studies.
Finally, the inconsistent use of adjunctive corticosteroids
in patients with suspected tuberculous pericarditis illus-
trates the controversy surrounding the effectiveness of
these agents in this setting [26]. A large randomised con-
trolled trial of the effectiveness of adjunctive corticoster-
oids is required to address this issue, particularly in HIV
infected individuals.
Table 6: Results of pericardial fluid analyses by clinical HIV status
Feature Clinical HIV disease No clinical HIV disease P
Pericardiocentesis
Indication:
31 (44.9) 38 (55.1) 0.29
 Diagnostic
14 (45.2) 17 (54.8) 0.97
 Therapeutic
17 (44.7) 21 (55.3)
Pericardial aspirate analyses:
Adenosine deaminase (n)
 > 40 IU/L
8 (42.1) 11 (57.9) 0.79
 < 40 IU/L
7 (46.7) 8 (53.3)
Ziehl-Neelsen stain for acid-fast 
bacilli (n)
 Positive
3 (42.9) 4 (57.1) 0.62
 Negative
20 (40.8) 29 (59.2)
TB culture (n)
 Positive
2 (33.3) 4 (66.7) 0.61
 Negative
4 (40.0) 6 (60.0)
Values are absolute counts (percentages)
IU/L: international units per litre.
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